Pfizer Inc. (NYSE:PFE – Get Free Report) declared a quarterly dividend on Wednesday, October 9th, RTT News reports. Shareholders of record on Friday, November 8th will be given a dividend of 0.42 per share by the biopharmaceutical company on Monday, December 2nd. This represents a $1.68 annualized dividend and a yield of 5.56%.
Pfizer has raised its dividend payment by an average of 2.6% annually over the last three years and has increased its dividend every year for the last 15 years. Pfizer has a dividend payout ratio of 58.7% meaning its dividend is sufficiently covered by earnings. Analysts expect Pfizer to earn $2.84 per share next year, which means the company should continue to be able to cover its $1.68 annual dividend with an expected future payout ratio of 59.2%.
Pfizer Price Performance
NYSE PFE opened at $30.20 on Thursday. Pfizer has a fifty-two week low of $25.20 and a fifty-two week high of $33.92. The stock’s 50-day moving average is $29.09 and its two-hundred day moving average is $28.35. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The firm has a market cap of $171.10 billion, a P/E ratio of -503.25, a price-to-earnings-growth ratio of 1.23 and a beta of 0.67.
Wall Street Analyst Weigh In
Several equities analysts recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Thursday, October 3rd. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Wednesday. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. UBS Group boosted their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a report on Wednesday, July 31st. Finally, Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.
Get Our Latest Analysis on PFE
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Recommended Stories
- Five stocks we like better than Pfizer
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- The Future of Medical Devices: Two Strong Buys You Can’t Miss
- How to Calculate Options Profits
- 3 Momentum Trades for October With Ample Upside Ahead
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Roblox Dips on Short Report—Here’s Why It Could Bounce Back Fast
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.